Tomer Mark is an Oncology physician affiliated with Genmab. OpenAlex indexes 246 publications with 5,062 citations (h-index 31); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
University Of Colorado Hospital
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 7 Oct 2016.
Clinical trials
- Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
Sponsor: Weill Medical College of Cornell University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20221 payment
- BeiGene USA, Inc.Program year20221 payment
- Karyopharm Therapeutics Inc.Program year202112 payments$17,935openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
32.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor32.4%Acyclovir100%Part D≥15 patientsCancer & immunology
24.1%Thalidomide Analog24.1%Revlimid100%Part D≥13 patientsBlood & clotting
14.7%Factor Xa inhibitor14.7%Eliquis56%Xarelto44%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”